IloperidoneDopamine (D2) and serotonin (5HT2) receptor antagonist CAS# 133454-47-4 |
- Celastrol
Catalog No.:BCN5986
CAS No.:34157-83-0
- BMS-345541
Catalog No.:BCC1423
CAS No.:547757-23-3
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Bay 65-1942 R form
Catalog No.:BCC1410
CAS No.:758683-21-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 133454-47-4 | SDF | Download SDF |
| PubChem ID | 71360 | Appearance | Powder |
| Formula | C24H27FN2O4 | M.Wt | 426.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (117.24 mM; Need ultrasonic) | ||
| Chemical Name | 1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanone | ||
| SMILES | CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC | ||
| Standard InChIKey | XMXHEBAFVSFQEX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Iloperidone Dilution Calculator
Iloperidone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3448 mL | 11.7239 mL | 23.4478 mL | 46.8955 mL | 58.6194 mL |
| 5 mM | 0.469 mL | 2.3448 mL | 4.6896 mL | 9.3791 mL | 11.7239 mL |
| 10 mM | 0.2345 mL | 1.1724 mL | 2.3448 mL | 4.6896 mL | 5.8619 mL |
| 50 mM | 0.0469 mL | 0.2345 mL | 0.469 mL | 0.9379 mL | 1.1724 mL |
| 100 mM | 0.0234 mL | 0.1172 mL | 0.2345 mL | 0.469 mL | 0.5862 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Iloperidone is an anti-psychotic combined dopamine (D2) and serotonin (5HT2) receptor antagonist.
- Heudelotinone
Catalog No.:BCN6180
CAS No.:133453-58-4
- Angophorol
Catalog No.:BCN3965
CAS No.:133442-54-3
- 3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone
Catalog No.:BCN1583
CAS No.:1334309-44-2
- PF 1022A
Catalog No.:BCC8064
CAS No.:133413-70-4
- MG-115
Catalog No.:BCC1237
CAS No.:133407-86-0
- MG-132
Catalog No.:BCC1227
CAS No.:133407-82-6
- (+)-Aflavazole
Catalog No.:BCN7339
CAS No.:133401-09-9
- 3-MPPI
Catalog No.:BCC6705
CAS No.:133399-65-2
- Brandioside
Catalog No.:BCN6770
CAS No.:133393-81-4
- Fmoc-β-Homo-D-Tyr(tBu)-OH
Catalog No.:BCC2620
CAS No.:133373-24-7
- 4-Hydroxy-11,12,13-trinor-5-eudesmen-7-one
Catalog No.:BCN6627
CAS No.:133369-42-3
- Fmoc-His(MMt)-OH
Catalog No.:BCC3503
CAS No.:133367-33-6
- Fmoc-Glu(OAll)-OH
Catalog No.:BCC3492
CAS No.:133464-46-7
- TAI-1
Catalog No.:BCC5576
CAS No.:1334921-03-7
- SR 1001
Catalog No.:BCC6309
CAS No.:1335106-03-0
- Exendin-3 (9-39) amide
Catalog No.:BCC7257
CAS No.:133514-43-9
- Apigenin 4'-O-rhamnoside
Catalog No.:BCN6181
CAS No.:133538-77-9
- AG-490
Catalog No.:BCC2193
CAS No.:133550-30-8
- Tyrphostin B44, (-) enantiomer
Catalog No.:BCC6703
CAS No.:133550-32-0
- AG 555
Catalog No.:BCC6721
CAS No.:133550-34-2
- AG 494
Catalog No.:BCC6722
CAS No.:133550-35-3
- Tyrphostin B44, (+) enantiomer
Catalog No.:BCC6704
CAS No.:133550-37-5
- AG 556
Catalog No.:BCC6720
CAS No.:133550-41-1
- 4,15-Isoatriplicolide methylacrylate
Catalog No.:BCN7935
CAS No.:133559-38-3
Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.[Pubmed:28008301]
Core Evid. 2016 Dec 14;11:49-61.
INTRODUCTION: Schizophrenia is a chronic and debilitating mental disorder that affects the patient's and their family's quality of life, as well as financial costs and health care settings. Despite the variety of available antipsychotics, optimal treatment outcomes are not always achieved. Novel drugs, such as Iloperidone, can provide more effective, tolerable and safer strategies. AIM: To review the evidence for the clinical impact of Iloperidone on the treatment of patients with schizophrenia. EVIDENCE REVIEW: Clinical trials, observational studies and meta-analyses reached a common consensus that Iloperidone is as effective as haloperidol, risperidone and ziprasidone in reducing schizophrenia symptoms. Similar amounts of adverse events and discontinuations were observed with Iloperidone compared to placebo and active treatments. Common adverse events are mild and include dizziness, hypotension, dry mouth and weight gain. Iloperidone can induce extension of QTc interval, and clinicians should be aware of its contraindications. In long-term trials, Iloperidone also showed promising safety and tolerability profiles. The low propensity to cause akathisia, extrapyramidal symptoms (EPS), increased prolactin levels or changes to metabolic laboratory parameters support its use in practice. Results showed that Iloperidone prevents relapse in stabilized patients, with a time to relapse superior to placebo and similar to haloperidol. Patients using a prior antipsychotic (eg, risperidone and aripiprazole) can easily switch to Iloperidone with no serious impact on safety or efficacy. However, the acquisition costs of Iloperidone may hamper its use. Further evidence comparing Iloperidone with other antipsychotics, and pharmacoeconomic studies would be welcome. PLACE IN THERAPY: Considering just the clinical profile of Iloperidone, it represents a promising drug for treating schizophrenia, particularly in patients who are intolerant to previous antipsychotics, as well as being suitable as first-line therapy. Cost-effectiveness comparisons are needed to justify its use in clinical practice.
A case of iloperidone overdose in a 27-year-old man with cocaine abuse.[Pubmed:27570623]
SAGE Open Med Case Rep. 2016 Aug 8;4:2050313X16660485.
INTRODUCTION: Iloperidone is a recently introduced antipsychotic medication. It is approved for the treatment of schizophrenia. There are no published reports of Iloperidone overdosage, but there are eight cases that have been reported to the US Food and Drug Administration. CASE REPORT: A case of a 27-year-old man who took 84 mg of Iloperidone while also smoking cocaine is described. He developed a prolonged QTc (527 ms) without arrhythmias and respiratory failure with mandated respiratory support. He ultimately recovered without sequelae. DISCUSSION: The information regarding previous cases of toxicity on the US Food and Drug Administration website is incomplete. However, there were no fatalities due to Iloperidone over-ingestion. Prolongation of the QTc may be a common feature.
Influences of CYP2D6(*)10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.[Pubmed:27665849]
Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
AIM: Iloperidone is an atypical antipsychotic drug that is mainly metabolized by CYP2D6, CYP3A4, and cytosolic enzymes. Previous studies show that extensive and poor metabolizers of CYP2D6 exhibit different plasma concentrations of Iloperidone and its metabolites. The aim of this study was to develop a parent-metabolite population pharmacokinetic (PPK) model to quantify the effects of CYP2D6(*)10 allele on the pharmacokinetics of Iloperidone and its metabolites in Chinese schizophrenia patients. METHODS: Seventy Chinese schizophrenia patients were enrolled, from whom limited blood samples were collected on d 15 (0 h) and d 28 (0, 4 and 12 h after drug administration). The plasma concentrations of Iloperidone and its metabolites M1 (P-88) and M2 (P-95) were simultaneously detected using a validated HPLC-MS assay. CYP2D6(*)10 (rs1065852) genotyping was performed. A PPK model was developed based on data from the patients using the NONMEM software (version 7.2). A one-compartment model with first-order absorption and elimination was used to describe the pharmacokinetic data related to Iloperidone and its metabolites. RESULTS: Patients with the CYP2D6(*)10 T/T genotype had significantly higher concentrations of Iloperidone and M1, and lower concentrations of M2 than the patients with C/C or C/T genotypes. The CYP2D6(*)10 genotype affected the elimination constants for transformation of Iloperidone to the metabolites M1 (K23) and M2 (K24). The K23 value of the patients with T/T genotype was 1.34-fold as great as that of the patients with C/C or C/T genotype. The K24 value of the patients with C/T and T/T genotypes was 0.693- and 0.492-fold, respectively, as low as that of the patients with C/C genotype. CONCLUSION: CYP2D6(*)10 mutations affect the pharmacokinetics of Iloperidone and its metabolites in Chinese schizophrenia patients, suggesting that the clinical doses of Iloperidone for patients with CYP2D6(*)10 mutations need to be optimized.
